Cerity Partners LLC Invests $438,000 in BioLife Solutions, Inc. (NASDAQ:BLFS)

Cerity Partners LLC purchased a new stake in BioLife Solutions, Inc. (NASDAQ:BLFS) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 26,941 shares of the medical equipment provider’s stock, valued at approximately $438,000. Cerity Partners LLC owned 0.06% of BioLife Solutions as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently bought and sold shares of BLFS. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of BioLife Solutions by 8.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,622 shares of the medical equipment provider’s stock valued at $216,000 after purchasing an additional 1,164 shares during the period. Roubaix Capital LLC acquired a new position in BioLife Solutions in the third quarter worth $2,029,000. Allspring Global Investments Holdings LLC boosted its holdings in BioLife Solutions by 88.4% in the third quarter. Allspring Global Investments Holdings LLC now owns 11,346 shares of the medical equipment provider’s stock worth $157,000 after purchasing an additional 5,324 shares during the period. Kornitzer Capital Management Inc. KS boosted its holdings in BioLife Solutions by 26.3% in the third quarter. Kornitzer Capital Management Inc. KS now owns 88,800 shares of the medical equipment provider’s stock worth $1,226,000 after purchasing an additional 18,500 shares during the period. Finally, American Financial Group Inc. boosted its holdings in BioLife Solutions by 12.5% in the third quarter. American Financial Group Inc. now owns 29,602 shares of the medical equipment provider’s stock worth $409,000 after purchasing an additional 3,286 shares during the period. Hedge funds and other institutional investors own 93.24% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Jefferies Financial Group began coverage on BioLife Solutions in a research note on Thursday, April 4th. They issued a “buy” rating and a $22.00 target price on the stock. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $23.40.

Insider Buying and Selling

In related news, Director Amy Duross sold 6,135 shares of BioLife Solutions stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $16.86, for a total value of $103,436.10. Following the transaction, the director now owns 34,508 shares of the company’s stock, valued at approximately $581,804.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Sarah Aebersold sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $17.65, for a total value of $70,600.00. Following the completion of the sale, the insider now owns 65,843 shares of the company’s stock, valued at approximately $1,162,128.95. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Amy Duross sold 6,135 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $16.86, for a total value of $103,436.10. Following the completion of the sale, the director now directly owns 34,508 shares of the company’s stock, valued at approximately $581,804.88. The disclosure for this sale can be found here. In the last quarter, insiders have sold 33,996 shares of company stock valued at $562,145. 2.70% of the stock is owned by corporate insiders.

BioLife Solutions Price Performance

Shares of NASDAQ BLFS opened at $16.86 on Friday. The company has a quick ratio of 1.83, a current ratio of 2.86 and a debt-to-equity ratio of 0.06. The firm’s 50-day simple moving average is $17.38 and its 200 day simple moving average is $15.42. BioLife Solutions, Inc. has a fifty-two week low of $8.92 and a fifty-two week high of $24.50. The stock has a market cap of $763.76 million, a P/E ratio of -10.85 and a beta of 1.67.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Thursday, February 29th. The medical equipment provider reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.02. BioLife Solutions had a negative net margin of 46.37% and a negative return on equity of 13.36%. The firm had revenue of $32.73 million for the quarter, compared to analysts’ expectations of $32.70 million. Equities analysts expect that BioLife Solutions, Inc. will post -0.6 EPS for the current year.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.